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Abstract
Background: We present an effective, rapid, systematic data mining approach for identifying
genes or proteins related to a particular interest. A selected combination of programs exploring
PubMed abstracts, universal gene/protein databases (UniProt, InterPro, NCBI Entrez), and state-
of-the-art pathway knowledge bases (LSGraph and Ingenuity Pathway Analysis) was assembled to
distinguish enzymes with hydrolytic activities that are expressed in the extracellular space of cancer
cells. Proteins were identified with respect to six types of cancer occurring in the prostate, breast,
lung, colon, ovary, and pancreas.
Results: The data mining method identified previously undetected targets. Our combined strategy
applied to each cancer type identified a minimum of 375 proteins expressed within the extracellular
space and/or attached to the plasma membrane. The method led to the recognition of human
cancer-related hydrolases (on average, ~35 per cancer type), among which were prostatic acid
phosphatase, prostate-specific antigen, and sulfatase 1.
Conclusion: The combined data mining of several databases overcame many of the limitations of
querying a single database and enabled the facile identification of gene products. In the case of
cancer-related targets, it produced a list of putative extracellular, hydrolytic enzymes that merit
additional study as candidates for cancer radioimaging and radiotherapy. The proposed data mining
strategy is of a general nature and can be applied to other biological databases for understanding
biological functions and diseases.
Background
Recent advances in genomics and associated high
throughput technologies have resulted in the exponential
growth of biological databases. These consist of annotated
genomic databases such as those at NCBI Genomic Biol-
ogy [1], Ensembl [2] and UCSC Genome Bioinformatics
[3]; specialized primary databases of proteins including
UniProt (the universal protein resource) [4] and the RCSB
Protein Data Bank (PDB, the database of protein struc-
tures) [5]; and derived databases such as EMBL-EBI Inter-
Pro (database of protein families, domains and functional
sites) [6]. In parallel with structured data, the corpus of
scientific literature (textual data) has been expanding rap-
idly. Structured and textual data are fertile grounds in the
bioinformatics community for the development of data
mining tools to identify key entities (genes/proteins)
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involved in biological processes and provide important
biological insights. The combination of these two
resources has resulted in knowledge bases that represent
derived information on interactions among entities (see
references [7-12]).
Deriving biological insights from these unprecedented
quantities of data is a challenge [13-16]. In recent years,
tools for data mining retrieval of information have made
considerable progress [17-20]. However, several problems
persist: (i) incorrect, incomplete or several (synonyms,
homonyms etc.) descriptions of entities, (ii) inefficient
search engines associated with databases, (iii) constant
need for annotation updates and for query-tool improve-
ments, and (iv) inherent complexity of the biological phe-
nomena and biological systems [17,21,22]. Moreover,
various databases and their associated tools provide infor-
mation at different levels of reliability and accuracy [21].
We present a systematic strategy for data mining that aims
to address the above-mentioned problems (Figure 1). It is
based on (i) use and combination of several resources (lit-
erature text, structured databases and knowledge bases),
(ii) retrieval capabilities of text mining tools selected for
this purpose, (iii) search within the Gene Ontology (GO)
[23] and filtering of entities by GO terms within knowl-
edge bases, and (iv) enlargement of the searched space by
functionally-related entities. The strategy is conceived so
that it can be used by any researcher for a particular prob-
lem. The intent is to develop a facile and reliable data
mining approach that allows the identification of new tar-
gets.
To develop the appropriate strategy, we have explored and
tested the performance of various data mining tools and
databases to arrive at a protocol that is most appropriate
for addressing our needs as well as those of users with
other criteria. Specifically, our sequence of procedures
Data mining tools and strategy Figure 1
Data mining tools and strategy. Building effective data mining strategy and the sequence of programs used in the proposed 
strategy.
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examined PubMed abstracts [24], gene/protein databases
– UniProt [4] and NCBI Entrez Gene [25], and state-of-
the-art pathway knowledge bases – IT.Omics LSGraph® [8]
and Ingenuity® Systems, Ingenuity Pathway Analysis [9].
The method was applied to the identification of cancer-
related enzymes with hydrolytic activities that are overex-
pressed in the extracellular space of solid tumor cells. The
developed strategy was evaluated by determination of
hydrolases suitable for our in-house EMCIT (Enzyme-
Mediated Cancer Imaging and Therapy) technology [26],
which aims to precipitate water-soluble radioactive prod-
rugs within the extracellular spaces of solid human
tumors for their diagnosis and/or therapy. In general,
these proteins are attached to the membrane via glycopol-
yinositol (GPI) linkers or they are secreted in the extracel-
lular space.
We have used the method to distinguish hydrolases that
are overexpressed by human prostate, breast, lung, colon,
ovarian, and pancreatic cancers. The approach has led to
the recognition of a number of cancer-related putative tar-
gets for the EMCIT technology, including prostatic acid
phosphatase (PAP), prostate-specific antigen (PSA), and
sulfatase 1 (SULF1). Finally, the strategy and selected
tools have helped us to determine several proteins that
may be useful in other fields of cancer biology, specifically
in the identification of biomarkers valuable in diagnosis,
prognosis, and therapy [27-30].
Results and discussion
Strategy setting
The basic idea is the development of a series of data min-
ing steps of increasing stringency such that the huge
number of entities (genes/proteins) present in the litera-
ture and in various databases is reduced to a manageable
size. At each step, the criteria, choice of tool, and data-
bases are selected by the user to increase the list of identi-
fied hits. We employ LSGraph and IPA as suggested in this
section; however, depending on the availability of tools or
the focus of the user, other tools and databases can be
"plugged in" to the proposed data mining strategy.
Our method using LSGraph [8] and Ingenuity Pathway
Analysis (IPA) [9] applications (complemented by GO
and PubMed) is founded on the combination of selected
tools and the comparison of the identified resulting hit
list with that provided by independent searches of the lit-
erature (A), knowledge bases (B), gene/protein databases
(C), and retrieval of information from the text by the
reader (manual review, D) (Figure 1). The method pro-
vides overall the largest list of proteins with desired prop-
erties.
The function of a protein is described in most detail in the
scientific publications. However, due to the condensed
nature of abstracts, scarce annotations in gene/protein
databases, and the complexity of biological systems, this
information may be difficult to acquire and to integrate.
Therefore the first step in our strategy is based on the selec-
tion of the tool that, if possible, recognizes term variations
within the text (in the full-text article preferably) and has
the capability to retrieve entities from the text and export
them to the list (here using LSGraph, PubMed).
Since we are mining for "unknown" proteins within a par-
ticular cellular location (extracellular, cell surface, plasma
membrane, GPI-anchored), the second step of the strategy
uses Gene Ontology as a tool in the process (using
LSGraph). The inclusion of filtering by Gene Ontology
organizing principles will allow any user to identify new
targets for a particular problem. This can be applied to any
search within the context of biological process, molecular
function, or cellular component.
A protein may be implicated in a function or a disease
because of its ability to interact with another protein that
is already known in that function or disease. A straightfor-
ward search for proteins concerned with a specific func-
tion may not reveal all those involved. The third step of
the present strategy includes the enlargement of the hit list
to functionally related neighbors, which may compensate
for the missing information and unmask the so-far-unre-
vealed protein function. In our particular case, this would
ascertain the identification of entities involved in cancer.
Therefore, we have extended the search to functionally
related genes and proteins (using LSGraph and IPA).
Selection of tools and databases
The performance of the combined searches is compared
with that employing exclusively either a single literature
or a database data mining method. The query of PubMed
only (method A), with subsequent retrieval and reading of
full texts one-by-one (method D) and the identification of
desirable entities, is time- and labor-intensive. The search
using Thomson RefViz™ [31] and Quosa™ [32] (see Meth-
ods) leads to the clear interconnection of abstracts and
limits the number of publications to be studied. These
programs, however, cannot be used to extract the assign-
ment of names, synonyms, and symbols to their appropri-
ate entities (genes/proteins) and to save them as a set;
thus, the list of entities of interest cannot be easily and
routinely generated. In contrast, LSGraph has literature
and entity retrieval capabilities that make it a suitable
tool.
Method C also has its shortcomings. Generally, databases
provide their own query tools that may produce biased
results. The problem consists of (i) incomplete or mis-BMC Bioinformatics 2006, 7:354 http://www.biomedcentral.com/1471-2105/7/354
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leading protein annotations, (ii) unsatisfactory query-
engine capabilities of protein databases, and (iii) unclear
or incomplete functional description. Retrieved results are
often specific database limited: databases differ from each
other and are not updated regularly or their updates are
not synchronized. Searching for functionally related pro-
teins is sometimes not possible. In comparison with the
combined data mining approach, protein-database search
is inefficient (even though these databases represent the
largest protein information depositories). For example,
the query for prostate extracellular protein results in only
3 to 5 hits (depending on the depository searched),
whereas our novel strategy produces 135 hits (Table 1).
Method B employs the LSGraph and Ingenuity Pathway
Analysis (IPA) pathway knowledge bases. We have com-
bined the advantages of both of these applications in
order to optimize the yield of the data mining process.
Moreover, they have the capability to import and visualize
the expression-fold of genes from microarray experi-
ments.
The essential power of LSGraph is its ability to identify all
relevant entities in all PubMed abstract citations («Most
cited entities» function, see Methods) and to cluster them
subsequently into a set. LSGraph incorporates the system
of functional and process-oriented annotations, based on
the Gene Ontology (GO), which allows selecting the enti-
ties associated with GO terms «extracellular region» or
«membrane». Both Gene Ontology terms have been
selected because they deliver the highest number of rele-
vant hits. Although the results include transmembrane-
and mitochondrial-membrane-associated proteins, these
can be removed later by limiting the search to a desired
subcellular location in IPA.
Ingenuity Pathway Analysis [9] is an application built on
one of the largest knowledge bases (Ingenuity Pathway
Knowledge Base), acquired by manual curation of full
texts of peer-reviewed scientific publications. It covers
information on more than 23,900 mammalian genes and
thousands of corresponding proteins and their relations
(1.4 million biological findings, December 2005) [9].
Enlargement of the set of extracellular entities (defined by
LSGraph) by functional neighbors of the IPA knowledge
base and subsequent focusing on entities discussed in the
context of cancer have enabled us to select entities suitable
as targets for EMCIT drug design (Figure 2). Both LSGraph
and IPA contain information about human, mouse and
rat species. If the mining is required for other species, e.g.
plants or yeast, it is possible to plug into the strategy dis-
cussed above the appropriate tools and databases. Hence,
the strategy will remain essentially identical and, within
the scope of selected tools, is generic in nature; we can
address various biological problems, for example, investi-
gate the genes involved in aggregation of proteins in
Alzheimer disease or identify key players and novel targets
in pathways involved in this disease.
Table 1: Number of enzyme hits identified in six common cancer types using the combined data mining strategy.a
Tumor type Prostate Breast Lung Colon Ovary Pancreas
PubMed: Abstracts about tissue types 89839b 203938 644380 133660 147373 164890
LSGraph: Abstracts with entity-to-entity functional relations in different tumor-
tissue types (function «filter»)
10857 23875 42962 15808 24758 28356
LSGraph: Abstracts remaining after filtering for keywords «extracellular» or 
«membrane»
1784 3873 8869 4815 4683 5305
LSGraph: All cited entities retrieved from filtered abstracts (function «Most 
cited entities»)
1791c 2500 4325 3030 3365 3059
LSGraph: Entities filtered additionally by Gene Ontology (function «Best GO») 
with the cellular component «extracellular region» or «membrane». Exported to 
IPA through UniProt accession numbers
749 941 1718 1186 1427 1244
IPA: Imported entities overlaid onto a global molecular network of IPA and 
enlarged by functionally related entities
917 1117 1954 1408 1675 1495
IPA: Entities within the network «cancer»d 375 456 598 481 515 450
IPA-location: Extracellular space 135 170 212 176 184 170
IPA-location: Plasma membrane 188 220 298 238 262 219
IPA-location: Extracellular space and Plasma membrane 323 390 510 414 446 389
IPA-family: Enzymes 12 14 20 17 16 16
IPA-family: Peptidases 24 25 33 24 30 31
IPA-family: Phosphatases 5 9 10 7 8 5
Other IPA-familiese 282 342 447 366 392 337
aCompleted on 11/18/05; bin italic: number of abstracts; cin normal font: number of entities (genes and proteins); dnumbers below correspond to 
subnetworks of entities designated by IPA-location or IPA-family and are all part of the IPA cancer network; eincludes some enzymes, for example 
human sulfatase 1BMC Bioinformatics 2006, 7:354 http://www.biomedcentral.com/1471-2105/7/354
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Cancer-related data mining case
The combined strategy using LSGraph and IPA (including
PubMed, GO, and UniProt) (Figure 1) has led to the find-
ings summarized as numbers of abstracts and proteins in
Table 1, these being acquired in a period of a few weeks.
The search for hydrolytic enzymes has been performed for
six common tumor tissues (prostate, breast, lung, colon,
ovary, and pancreas). First, a PubMed query has yielded
between 90,000 to more than 640,000 articles per specific
cancer-tissue type. Using the «filter» function in LSGraph
reduces this number to between 11,000 and 42,000
abstracts containing sentences that describe entity-to-
entity functional relations. The next step, which involves
sifting for the keywords «extracellular» or «membrane»,
decreases these numbers to approximately 1,784 to 8,869
entities implicated in the extracellular environment,
which corresponds to about 1,791 to 4,325 proteins. Fur-
ther filtering by the Gene Ontology database in LSGraph
annotates 749 to 1,718 proteins as extracellular or mem-
brane-bound.
Over 375 enzymes, receptor domains, growth factors and
other proteins have been found in the context of the six
tumor-tissue types linked to «cancer». Using the IPA, 375
to 598 of these proteins are found to be within the «can-
cer» network (Table 1). The majority of the identified
extracellular proteins for all tumor types are growth fac-
tors, tumor necrosis factors [33], and hydrolytic enzymes.
The latter are placed within "Enzymes," "Peptidases,"
"Phosphatases," and other IPA families (Table 1). Further
reading of the cited articles, retrospectively tracked by
iHOP [34], has enabled us to select those that are appro-
priate for our in-house EMCIT concept. The list of hits is
enclosed with this article on-line, see Additional file 1.
From this final dataset, we have identified several hydro-
lases, among them peptidases (matrix metalloproteinases
and kallikreins) and phosphatases (see Figure 3 for IPA
subnetwork) and several known cancer progression mark-
ers, matrix metalloproteinases (MMP1, MMP2, MMP3,
MMP7, MMP9) [35] and coagulation factors II, III, XII
(Hageman factor, F11), located at the extracellular surface
[35,36]. Another potential target retrieved in all six cancer
types is cathepsin B, a hydrolase expressed in brain tumors
and suggested as an agent for the imaging of tumor pro-
gression [33].
There are also apparent pitfalls/shortcomings in the
knowledge bases. In IPA, for instance, the cellular compo-
nent annotation is sometimes missing or incomplete due
to the lack of information in protein databases to which
IPA is ultimately linked (e.g. UniProt, Pfam [37], Entrez
Gene). In the case of cellular location, this could mean
Transfer of entities between two knowledge bases Figure 2
Transfer of entities between two knowledge bases. For LSGraph, PubMed and GO, all extracellular or membrane-
bound entities cited in scientific abstracts were exported using UniProt accession numbers into IPA (thick arrow) for each can-
cer type. For IPA, imported entities were recognized and enlarged by functional neighbors (shaded area) of «Global Analysis 
Genes» network. All entities with «High Level Function» corresponding to «cancer» (thin arrows) were exported to Microsoft 
Excel workbook as hit lists for further individual examination (see Additional file 1).
Import 
to IPA
LSGraph IPABMC Bioinformatics 2006, 7:354 http://www.biomedcentral.com/1471-2105/7/354
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that the set of extracellular entities may be an underesti-
mate and that the 135 hits found, for example, in prostate
cancer may be only a subset. Links to curated databases
are valuable; however, the major knowledge is still hidden
in the full text of the scientific literature.
Identification of promising targets
Prostatic acid phosphatase
The success of our strategy can be demonstrated in the
identification of PAP (for our purposes as an EMCIT can-
didate). In UniProt, the prostatic acid phosphatase (PAP,
gene name ACPP) is not found when three keywords are
used: "prostate", "acid" and "phosphatase." This problem
has a crucial impact when searching through databases.
Generally, restricting the scan to annotation fields of data-
bases (UniProt or Entrez Gene [25]) is faster but doing so
can provide an outcome that is limited by the ad hoc rela-
tionship of keywords to the research interests of whoever
submitted the entry. Analogically, we observe similar
problems when using NCBI protein or nucleotide data-
bases, InterPro, PDB, OMIM™ (Online Mendelian Inherit-
ance in Man, database of human genes and genetic
disorders) [38] and Pfam (protein families database).
Moreover keeping annotations current is difficult as new
information appears frequently and regularly in the liter-
ature. When searching for proteins with specific properties
Example of network of prostate-cancer-related proteins Figure 3
Example of network of prostate-cancer-related proteins. This network was generated through the use of Ingenuity 
Pathway Analysis (IPA). Gene products are represented as nodes and biological relationships between two nodes as a line. 
Shapes of nodes symbolize functional class of gene product; for example, triangles are phosphatases, diamond-shaped rectan-
gles are peptidases. Proteins are separated in spaces between lines corresponding to cellular location based on IPA-location 
categories: Extracellular space, Plasma membrane, Cytoplasm, and Nucleus. Some proteins of interest are circled: prostatic 
acid phosphatase (PAP) is coded as ACPP, prostate-specific antigen (PSA) as KLK3 (kallikrein 3), and various metalloprotein-
ases as MMP.
Extracellular
Space
Plasma
Membrane
Cytoplasm
Nucleus
KLK3 = PSA
ACPP = PAPBMC Bioinformatics 2006, 7:354 http://www.biomedcentral.com/1471-2105/7/354
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without the knowledge of their actual name, symbol, or
database identifier, data mining has to be performed with
care.
Another issue with PAP is its cellular localization. While
this hydrolase possessing protein tyrosine phosphatase
activity has been demonstrated in vitro to dephosphor-
ylate the epidermal growth factor (EGF) receptor present
at an intracellular site in prostate carcinoma cells, PAP is
also known to be secreted by epithelial cells in the pros-
tate gland and found in seminal fluid (see references in
[39]). UniProt does not specify the location of PAP; Entrez
Gene provides the GO term "extracellular region" associ-
ated to PAP with a note that there is no record of it (NR,
no record). It is safe to assume that since PAP is secreted
outside cells, it will be localized in the extracellular space.
Our recent in vitro cell analysis using noninternalizable
PAP substrates shows that phosphorolysis occurs in the
extracellular region (unpublished results). The combined
data mining strategy ensures that PAP is not lost with the
filtering of the results. It is identified as "ACPP – acid
phosphatase, prostate" in LSGraph and situated by IPA in
the «cancer» network (Figure 3). Both LSGraph and IPA
document PAP as extracellular and, therefore, PAP has
been identified and passed through the data mining step
to the final list.
Alkaline phosphatase
Alkaline phosphatase (ALP) exemplifies another aspect of
the annotation problem that is addressed uniquely by our
strategy. This enzyme, known to be overexpressed at the
surface of various solid tumors [40-45], is one of the first
proteins identified as being expressed on the surface of
cancer cells [46]. Many clinical observations have been
made on the use of ALP as a tumor marker [47-50].
Searches for alkaline phosphatase in gene and protein
databases have identified 19 protein sequences in
humans, out of which only four are well-described: pla-
cental (gene name ALPP), placental-like (gene name
ALPPL2), intestinal (gene name ALPI) and nonspecific tis-
sue (liver/bone/kidney) (gene name ALPL). Databases
state that human ALP is bound to the membrane by a GPI-
anchor in contrast to mouse isoenzymes which are «extra-
cellular». This illustrates, retrospectively, why we have not
used the species specification in data mining. In the case
of ALPI, UniProt also registers the GO term «membrane».
For other ALP, the subcellular location is not present in
annotations (noted "none"). Curiously, a similar situa-
tion occurs with Entrez Gene registrations of ALPP, ALPI
and ALPL [Entrez Gene: 250, 248 and 249, respectively].
Due to this fact, the description of proteins as "attached to
the membrane by a GPI-anchor" does not access them if
searched for with "extracellular."
Specification of ALP searches in databases by the keyword
"cancer" or by other neoplasm-related terms does not
identify any of the above isoenzymes. UniProt annotation
states that the exact physiological function of the alkaline
phosphatases is not known [UniProt:PPB1_HUMAN].
Surprisingly, neither UniProt nor Entrez Gene (both of
which are large depositories of information) states that
these enzymes are related to cancer. In our data mining
findings, alkaline phosphatase is listed in LSGraph under
different isoenzymes (ALPP, ALPI etc.) in all six tissue
types studied. However, ALP is subsequently lost within
the IPA step of the data mining process due to missing
annotation in the original gene/protein databases as well
as its being placed within the IPA «cell-cell interactions»
network and not the «cancer» network. Therefore, unless
entries are thoroughly investigated one by one, a search
using simple keywords in gene or protein databases will
not identify alkaline phosphatase as an extracellular can-
cer-related enzyme.
Extracellular sulfatase 1
One of the new hits and a potential EMCIT target identi-
fied by the present strategy is a human enzyme, extracellu-
lar sulfatase 1 (SULF1) [51-53]. This enzyme is situated in
the endoplasmatic reticulum and Golgi stack and is also
shown, by its similarity to homologous proteins, to be
secreted outside the cell (as described in [Uni-
Prot:SULF1_HUMAN]. Although SULF1 contains the
word "extracellular" in its protein name (Extracellular sul-
fatase 1 precursor), protein databases do not track a trace-
able author statement or publication with reference to its
being an extracellular enzyme. Only Entrez Gene [Entrez
Gene:23213] states that it is extracellular, referring to
Morimoto-Tomita et al. [51]. Similar to the case with PAP,
we have recently also demonstrated the hydrolysis of a
noninternalizable sulfatase substrate by human pancre-
atic tumor cells, thereby ascertaining the presence of
SULF1 in the extracellular space (unpublished results).
Once more this demonstrates the idiosyncrasies of such
searches since the use of database-only data mining
(method  B) would not have identified this sulfatase
whose recognition within our hit list is consequent to the
utilization of a combination of programs and the search
within the space of functionally-related proteins.
Prostate-specific antigen
Another EMCIT candidate that has been established is
prostate-specific antigen (PSA), a well-known and clini-
cally useful prostate cancer marker that has proteolytic
activities. This molecule, also known as kallikrein 3
(KLK3), is secreted in the extracellular space (Figure 3) by
normal and malignant prostate cells [54,55]. Since this
enzymatically active molecule is inactivated by binding to
several protease inhibitors once it enters the circulation
[54,56,57], we and others [58] have recognized its poten-BMC Bioinformatics 2006, 7:354 http://www.biomedcentral.com/1471-2105/7/354
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tial for targeting PSA-activated prodrug molecules to pros-
tate cancer. PSA (under the name KLK3) has passed
through the data mining and was identified in all six can-
cer types (Figure 3, Additional file 1).
As mentioned above, our interest in the identification of
extracellular hydrolytic enzymes, such as prostatic acid
phosphatase, alkaline phosphatase, sulfatase 1 and pros-
tate-specific antigen, is driven by our focus on finding
novel, radiolabeled molecules that are excellent substrates
for such enzyme candidates, as these could be used to
hydrolyze the radiolabeled prodrugs for our EMCIT
approach. These enzymes can be further studied by in sil-
ico modeling simulations of their complexes with putative
drugs. The prerequisite for molecular modeling of pro-
tein-ligand complexes is the availability of the three-
dimensional (3D) structure for the target in the Protein
Data Bank (PDB) or, in its absence, the building of a 3D-
structure homology model. In our case, when these targets
were checked for 3D-structure availability in the PDB, it
was found that both PAP and ALP have already been crys-
tallized (PDB codes 1ND5 and 1EW2, respectively)
whereas the structures of human PSA (in contrast to that
of the horse homologue) and SULF1 have not yet been
solved.
Conclusion
We have developed a new, rapid, data mining strategy that
combines the literature, web-based gene-product data-
bases, and complex knowledge pathway databases. The
strategy, which is based on a combination of curated
knowledge pathway bases with protein databases, has
revealed the unique characteristics of several programs,
including the entity retrieval capability and the Gene
Ontology term-filtering specification of LSGraph and the
full-text-based knowledge of IPA. The complementarity of
content and functionalities of the query tools in the
knowledge bases help to ascertain the identified hits as
well as to discover other related neighbors of the known
targets. We believe that this strategy overcomes many data
mining drawbacks.
The application of this strategy to the search for extracel-
lular hydrolases involved in human cancers has led to the
discovery and identification of several previously "hid-
den" proteins that would not have been detected by a
search using a single information source. Our findings
indicate that the approach benefits from the complemen-
tarity of the databases and query tools employed and can
distinguish useful and previously uncharacterized cancer-
related targets with additional characteristics (other cellu-
lar localization, biological function) valuable in the non-
invasive radiodiagnosis and treatment of cancer. Alkaline
phosphatase (various cancers), prostatic acid phosphatase
and prostate-specific antigen (prostate cancer), and extra-
cellular sulfatase 1 (pancreatic cancer) are four interesting
results. While these are being used in our laboratory as
potential targets in the design of novel, radiolabeled diag-
nostic and therapeutic agents for cancer, the strategy for
data mining is of a general nature and can be applied to
other biological databases for understanding biological
functions and diseases.
Methods
A graphical representation including the steps of the strat-
egy of our data mining method is presented in Figure 1
and Table 1. The sequence of tools used in our strategy has
been determined after exploration of available tools and
databases (that were accessible to us) in four different
analysis components (Figure 1): literature databases (A),
knowledge pathway databases (B), annotated gene/pro-
tein databases (C), and manual review (D).
Literature (A)
The literature search (A) was done using PubMed and the
RefViz™ (version 1.1.0) [31] and Quosa™ (version 7.14)
[32] applications. RefViz and Quosa hunt through
PubMed [24], Web of Science® [59], and other literature
sources and use symbolical, graphical visualization to
explore the reference collections for the specific keyword.
Knowledge bases (B)
The functional relationship, knowledge-base search (B)
used the pathway analysis programs LSGraph (version
1.5, Life Science Graph®, IT.Omics, Lille, France) [8] and
Ingenuity Pathways Analysis (IPA) (version 2.0, Ingenu-
ity®  Systems, Mountain View, California, U.S.A.) [9].
LSGraph is free for academia and IPA provides (as do
other similar commercial programs) free trials. Explora-
tion was carried out for proteins with required character-
istics (extracellular or integral to membrane, related to
cancer). Both applications were used to enlarge the set of
entities by functionally related neighbors (Figure 2). For
both LSGraph and IPA, every entity functional relation-
ship in the networks is supported by published informa-
tion.
LSGraph and Gene Ontology
This application performs advanced bibliographic queries
in the abstracts of PubMed by desired keyword («filter»
function) and carries out exhaustive searches due to the
systematic coverage of synonyms and homonyms.
LSGraph can also interpret large-scale experimental data-
sets (microarrays). Its «Most cited entities» function
allows the retrieval of the entities that are discussed most
frequently in abstracts selected by «filter» function key-
word and exports them into the user-defined set (see in
detailed algorithm steps below). In our case, we set this
function so that we retrieved all entities in the current lit-
erature, ranked in order from most to least cited.BMC Bioinformatics 2006, 7:354 http://www.biomedcentral.com/1471-2105/7/354
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Additional LSGraph function «Best GO» of the Gene
Ontology can identify and rank all GO terms associated
with the entities and subsequently downsize the list based
on the GO term of choice. The Gene Ontology (GO)
project is a collaborative effort that aims to address the
need for consistent descriptions of gene products in differ-
ent databases [60]. The GO consortium is developing
three, structured, controlled vocabularies (ontologies)
that describe gene products in terms of their associated
biological processes, molecular functions, and cellular
components in a species-independent manner. We used
one of the organizing principles, cellular component, to
associate the searched gene products annotated with the
term «extracellular region» or «membrane». The «extracel-
lular region» term ([GO:0005576]; 4434 entities share
this term, December 2005) is hierarchically inferior
directly under the cellular component tree but does not
include proteins attached to the cell membrane. The term
«membrane» ([GO:0016020]; 17193 entities share this
term, December 2005) is attributed to proteins attached
or within the membranes enclosing cells or any mem-
branes of eukaryotic organelles. Later strategy-filtering
with IPA-location categories can distinguish the plasma
membrane specifically.
Ingenuity Pathway Analysis (IPA)
This is a web-based software application that allows users
to identify the biological mechanisms, pathways, and
functions most relevant to a dataset of genes or proteins of
interest. It is founded on the largest knowledge base of
biological networks created from millions of expert-
curated relationships between genes, proteins, cells, tis-
sues, drugs, and diseases. The networks linked to cancer
are generated from the full text of articles (contrary to
LSGraph) published in the most important scientific jour-
nals. Imported gene identifiers (here from LSGraph) are
mapped to its corresponding gene object in the Ingenuity
Pathways Knowledge Base (IPKB). These genes, called
focus genes, are overlaid onto a global molecular network
developed from information contained in the IPKB. Net-
works of these focus genes are then algorithmically gener-
ated based on their connectivity. The Functional Analysis
of IPA identifies the biological functions and/or diseases
that are most significant to the data set (e.g. cancer).
Databases (C)
The gene/protein database search (C) was performed
using the world's largest collections of genes and proteins,
UniProt [4], InterPro [6] and NCBI Entrez [61]. UniProt
(the Universal Protein Resource) is the catalog of informa-
tion on proteins created by joining the information con-
tained in Swiss-Prot, TrEMBL, and PIR. InterPro is a
derived database of protein families, domains, and func-
tional sites in which identifiable features found in known
proteins can be applied to unknown protein sequences. It
contains the most comprehensive and complete annota-
tions of proteins in various organisms. NCBI Entrez (The
Entrez Global Query Cross-Database Search System)
searches simultaneously against a set of databases for pro-
teins, genes, structures, conserved domains, homologues
and other criteria. These three databases were selected
based on our own experience, the content quantity and
quality, and the need to ensure that we maximally covered
the collections of gene products.
Manual review (D)
Manual review of the literature (D) was performed on the
full text of publications identified in PubMed queries
directly or indirectly through online links to references in
gene/protein databases.
Tools applied in our strategy
The combined strategy suggested in this work is conceived
as follows (Figure 1): use of an effective tool for entity
retrieval from the literature text and gene/protein data-
bases (LSGraph search in PubMed), selection (filter-
down) of entities upon the specific user-defined GO
terms, and subsequent enlargement of the entity list by
functional pathway neighbors (LSGraph and IPA). The
accuracy of the results was assessed using control proteins
that we know are extracellular and involved in cancer.
The comparison of data mining components A though D
led to the use of tools in the following sequence of steps
(Figure 1, Table 1: first column):
(i) Using analysis tools incorporated in LSGraph, we fil-
tered the complete corpus of the PubMed down to
abstracts that contain evidences of entity-to-entity rela-
tionship and are related to one of the six tumor-tissue
types. The keywords "cancer" or "tumor" were not used in
the query, but later in IPA (see (v)), because the evidence
for the disease at this level of the search may not necessar-
ily be known. Instead, the tissue names, prostate/pros-
tatic, breast, lung/pulmonary, ovary/ovarian, colon/
colonic, pancreas/pancreatic, which are present in the
abstracts, were used in the searches. To ensure that we
would not miss studies on model organisms such as the
mouse, the search was not limited to humans.
(ii) The LSGraph function «Most cited entities» was used
to extract all entities present in retrieved abstracts defined
by the «filter» keyword and order them from the most
cited to the least cited entity.
(iii) Entities with localization specified by cellular compo-
nent, «extracellular region», «membrane», of the Gene
Ontology database (LSGraph «Best GO») were saved in a
new set containing protein identifiers, viz. UniProt acces-
sion numbers.BMC Bioinformatics 2006, 7:354 http://www.biomedcentral.com/1471-2105/7/354
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(iv) The set with all UniProt identifiers was imported into
the IPA and thus enlarged by related entities (functional
neighbors) (Figure 2).
(v) The functional analysis of IPA can identify the biolog-
ical functions and/or diseases that are most significant to
the dataset. Genes from the dataset found to be associated
with "cancer" were considered for further analysis (Figure
2). Up to this point, the filtering was done for tissue type
only (prostate, breast, etc.) and not for the pathological
process of interest, i.e. cancer. From this point on, the enti-
ties were sifted down to the set known to be involved in
cancer by selecting the IPA subnetworks in which cancer
occurs as the most significant annotation. Figure 3 is an
example of subnetworks for prostate cancer.
(vi) The final set of filtered entities was exported and
stored in a Microsoft Excel spreadsheet (see Additional file
1) containing the gene product name, synonyms, descrip-
tion, UniProt accession number (AC), IPA-defined cellu-
lar localization and protein family.
(vii) The identified extracellular proteins that were
retained by the above-mentioned criteria were filtered by
IPA protein family (defined by Entrez Gene). The final
count of hits was compared with the number of hits iden-
tified by the literature search method (A) and the single
gene/protein database method (C).
Detailed analysis of resulting enzyme hits was done retro-
spectively in their most cited articles using iHOP (infor-
mation hyperlinked over proteins) [34], a program that
finds links to gene and protein databases (UniProt, PDB
and NCBI databases) and identifies the particular gene
product if the gene name or synonym name is known.
The proposed method is rapid, and the protocol can be
performed within several days. Steps (i) – (iii) are autom-
atized searches where only the filtering keyword entries or
GO term entries are required. Steps (iii) – (v) as well as
step (vii) require the manual export/import of the Uni-
Prot identifiers from LSGraph into IPA and from IPA into
Microsoft Excel file format. Resulting proteins hits with
enzymatic activities were confirmed manually by check-
ing the associated literature references; hydrolases were
confirmed among "Enzymes," "Peptidases," "Phos-
phatases," and other IPA families. Particular cases (see
Results and Discussion) were consulted in original publi-
cations.
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